Circulating proteomic signatures in blood plasma distinguish individuals with Parkinson’s disease from unaffected individuals and track cognitive vulnerability, according to findings from an observational study published in npj Parkinson’s Disease. A research team investigated longitudinal plasma proteomics to address the absence of reliable prognostic biomarkers for cognitive decline, which represents a primary source of long-term disability in Parkinson’s disease. By evaluating longitudinal blood samples collected across multiple timepoints, the investigators identified 284 plasma proteins that discriminated participants with Parkinson’s disease from healthy control subjects with an area under the receiver operating characteristic curve of 0.88.
The initial discovery analysis drew from the Parkinson’s Progression Markers Initiative, examining a total of 544 longitudinal plasma samples. This cohort comprised 199 samples obtained from 68 patients diagnosed with Parkinson’s disease alongside 345 samples provided by 115 healthy control participants. To profile the circulating proteome, the researchers used the Olink platform to quantify targeted protein abundances across the longitudinal specimens. Beyond classifying overall disease status, the investigators analyzed how circulating proteins correlated with clinical heterogeneity, specifically grouping 63 of the disease-associated proteins into five distinct co-expression modules linked directly to measures of cognitive performance. In structural neuroimaging evaluations, four of those five cognition-linked co-expression modules showed correlations with regional brain atrophy in at least one analysis.
To confirm the reliability of these findings, the authors conducted an independent cross-sectional validation using data from the Parkinson’s Disease Biomarkers Program. This replication cohort included 175 participants with Parkinson’s disease and 17 healthy controls whose blood specimens were analyzed using the SomaScan proteomic platform. Within these shared modules, the statistical associations for three specific lysosomal proteins—Cathepsin D, Cathepsin Z, and Cystatin C—replicated across the two independent patient cohorts.
Clinical correlation analyses demonstrated that elevated plasma levels of all three replicated lysosomal proteins—Cathepsin D, Cathepsin Z, and Cystatin C—were linked to both cognitive impairment and motor impairment among patients. The observed elevation of these circulating markers points toward an underlying biological disturbance, with the researchers identifying lysosomal protease dysfunction as a potential contributor to the disease process. These findings define a measurable plasma signature of cognitive vulnerability in Parkinson’s disease, showing that peripheral proteomic signatures correspond with both cognitive heterogeneity and clinical motor severity observed in affected individuals.
In an exploratory analysis aimed at forecasting disease trajectories, the investigators evaluated a predictive model that combined clinical variables with proteomic measurements. When tested on a held-out subset of participants with Parkinson’s disease, this combined clinical–proteomic model demonstrated preliminary predictive ability to forecast future cognitive decline, achieving an R² value of 0.365. The forecasting analysis was strictly exploratory and evaluated within a held-out participant subset. Furthermore, while the initial cohort evaluated longitudinal plasma samples, the replication in the Parkinson’s Disease Biomarkers Program was cross-sectional.
Subject of Research: Plasma proteomic biomarkers of cognitive decline in Parkinson's disease
Article Title: Plasma proteomic signatures of Parkinson’s disease status, cognitive heterogeneity and longitudinal decline
Article References: Louiset, R., Massart, R., Hue, S., Lunven, M., de Langavant, L. C., Salhi, H., Bachoud-Lévi, A.-C., & Rémy, P. (2026). Plasma proteomic signatures of Parkinson’s disease status, cognitive heterogeneity and longitudinal decline. npj Parkinson's Disease. https://doi.org/10.1038/s41531-026-01612-4
Image Credits: AI Generated
DOI: 10.1038/s41531-026-01612-4
Keywords: Parkinson's disease, plasma proteomics, cognitive decline, biomarkers, lysosomal dysfunction, Cathepsin D, Cathepsin Z, Cystatin C, PPMI cohort, PDBP cohort, Olink, SomaScan, co-expression modules, brain atrophy, motor impairment, prognostic modeling
News Source: Cassandra Pierce. (November 16, 2026). Plasma Proteomic Profiling Identifies Lysosomal Markers Linked to Parkinson’s Cognitive Decline. Scienmag.



